LONDON, May 3 (Reuters) – Is nanomedicine the next big
thing? A growing number of top drug companies seem to think so.

The ability to encapsulate potent drugs in tiny particles
measuring billionths of a metre in diameter is opening up new
options for super-accurate drug delivery, increasing precision
hits at the site of disease with, hopefully, fewer side effects.

LONDON, May 2 (Reuters) – Medical devices maker Smith &
Nephew is to hand back cash to shareholders through a
$300 million share repurchase programme.

The supplier of artificial hips and knees announced the
buyback on Thursday as part of a new capital allocation that
will also see a commitment to continuing investment and
acquisitions.

LONDON, April 30 (Reuters) – The head of Europe’s medicines
regulator is digging in for a fight over data transparency after
being stopped from releasing information on drugs from two U.S.
companies by a court ruling.

Defeat for the European Medicines Agency (EMA) at the hands
of AbbVie and Intermune highlights a growing
battle between campaigners for more openness and companies which
fear it will harm their business.

LONDON (Reuters) – Europe’s medicines regulator has been stopped from releasing clinical trial data about drugs made by AbbVie and Intermune, following a court ruling favoring the two U.S. companies.

The European Medicines Agency said on Tuesday it intended to appeal the interim decision by the European Union’s general court.

LONDON (Reuters) – British scientists are stepping up clinical tests of gene therapy in a bid to help people with advanced heart failure pump blood more efficiently.

Researchers said on Tuesday they planned to enroll patients into two new clinical trials using Mydicar, a gene therapy treatment made by privately held U.S. biotech company Celladon.